Overview
- The agreement, announced at the BIO 2026 convention on Monday, June 22, 2026, includes roughly $18 million in upfront and near‑term payments to Insilico and more than $2.5 billion in potential development, regulatory and commercial milestones plus single‑digit royalties.
- Under the deal Insilico will use its Pharma.AI platform for target validation, generative chemistry and molecule optimization while SK Biopharmaceuticals will lead late‑stage clinical development and commercialization through its U.S. arm, SK Life Science.
- Insilico says its AI platform reaches preclinical candidate nomination faster than traditional discovery, averaging 12–18 months per program and having nominated 31 preclinical candidate compounds since 2021 with 13 IND approvals or clearances.
- Investors reacted to the announcement with Insilico’s Hong Kong shares up about 5.6% on the day and SK Biopharmaceuticals’ shares down about 1.7%, reflecting investor interest in AI discovery and caution about development costs.
- The partnership follows Insilico’s March 2026 landmark deal with Eli Lilly and reflects a wider industry trend of pairing generative‑AI discovery platforms with established clinical and commercial partners to try to speed options for patients with neuroimmune and other hard‑to‑treat CNS conditions.